Predictive value of p16\textsuperscript{INK4a}, Ki-67 and ProExC immuno-qualitative features in LSIL progression into HSIL

LING DING\textsuperscript{1}, LI SONG\textsuperscript{1*}, WEIHONG ZHAO\textsuperscript{2}, XIAOXUE LI\textsuperscript{1}, WEN GAO\textsuperscript{1}, ZHUO QI\textsuperscript{1} and JINTAO WANG\textsuperscript{1}

\textsuperscript{1}Department of Epidemiology, School of Public Health, Shanxi Medical University; \textsuperscript{2}Department of Obstetrics and Gynecology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China

Received April 8, 2019; Accepted November 27, 2019

DOI: 10.3892/etm.2020.8496

Abstract. The current nested case-control study was conducted to explore the prognostic value of cyclin-dependent kinase inhibitor 2A (p16\textsuperscript{INK4a}), marker of proliferation Ki-67 (Ki-67) and immunohistochemical cocktail containing antibodies directed against topoisomerase II\textalpha{} (TOP2A) and minichromosome maintenance 2 (MCM2) proteins (ProExC) immuno-qualitative features to predict low-grade squamous intraepithelial lesion (LSIL) progression. A total of 92 LSIL patients were followed-up for 2 years, where those with high-grade squamous intraepithelial lesion (HSIL) or persistent LSIL were designated as the case group and those who spontaneously regressed were designated as the control group. The infection status of human papillomavirus (HPV) was evaluated using flow-through hybridization and gene chip, whilst the expression of p16\textsuperscript{INK4a}, Ki-67 and ProExC were tested in LSIL patient biopsies by immunohistochemistry. All data were collected at the beginning of the follow-up and patient outcomes were diagnosed by histopathological examination. To analyze the risk factors for LSIL progression, sensitivity, specificity, positive-negative predictive value (PPV-NPV), positive-negative likelihood ratio (PLR-NLR), Youden's index (YI) and multinomial logistic regression analysis was performed. The expression rates of p16\textsuperscript{INK4a}, Ki-67, and ProExC were found to be higher in the progression group compared with those in the persistence and regression groups. Only p16\textsuperscript{INK4a} expression significantly associated with high-risk HPV infection. With respect to predicting HSIL, p16\textsuperscript{INK4a} staining was the most sensitive but Ki-67 staining was found to be the most specific. YI was the highest (42.1%) for p16\textsuperscript{INK4a} expression in the present study, followed by ProExC (39.5%) and Ki-67 (28.3%). However, the expression of ProExC was found to be an independent risk factor for LSIL progression into HSIL. In conclusion, whilst immunohistochemical staining for p16\textsuperscript{INK4a}, Ki-67, and ProExC can be used to predict HSIL progression, only ProExC expression can be applied an independent risk factor for LSIL progression.

Introduction

Cervical cancer is the second most common female malignancy in China (1), where Shanxi Province is a particularly high-risk (HR) area; with a detection rate of 55-100,000 in Jiexiu (2), which is higher compared with the average incidence of 13.4-100,000 in China (3). Therefore, strategies to prevent the occurrence of cervical cancer in China, especially in Shanxi, are urgently required. Cervical cancer generally develops from pre-existing, non-invasive and squamous precursor lesions, referred to as cervical intraepithelial neoplasia (CIN) or squamous intraepithelial lesions (SIL), which also includes low-grade (LSIL) and high-grade SIL (HSIL). Since SIL develops gradually, early diagnosis is an important means of preventing cervical cancer. Although 60% of LSIL cases are transient and spontaneously regress within 12-24 months, LSIL do persist in 30% of the cases, where ~10% of LSIL develop into HSIL within 2 years (4). Since only a small percentage of patients with LSIL progress into HSIL, it is therefore preferable to identify patients with LSIL so that resection can be performed at an early stage, where they can be safely followed up using cervix cytology and colposcopy until the lesions regress. Although loop electrosurgical excision (LEEP) procedures can be performed on LSIL patients to avoid LSIL progression, this treatment can be considered excessive in addition to causing an economic burden on the healthcare system (5). Therefore, it is of medical and economical relevance to identify biomarkers that can distinguish patients with LSIL that are at high risk of progressing into HSIL and cervical cancer (6,7).

Among human papillomavirus (HPV)-infected individuals, only 1% will progress to cervical cancer (8-11). Investigations into the relationship between HPV and the host cell cycle have identified a number of biomarkers, including cyclin-dependent kinase inhibitor 2A (p16\textsuperscript{INK4a}), marker of...
proliferation Ki-67 (Ki-67) and immunohistochemical cocktail containing antibodies direct against topoisomerase IIα (TOP2A) and minichromosome maintenance 2 (MCM2) proteins (ProExC), which can be measured to improve the detection and grading of HPV-associated SIL, as they were found to be overexpressed in HPV-infected cells (12). p16\(^{INK4a}\) is a kinase inhibitor and tumor suppressor that regulates cell cycle progression in the G\(_1\)-S phase and inhibits cell proliferation through a reciprocal relationship with another tumor suppressor protein, retinoblastoma protein (pRb) (13). Ki-67 is a nuclear protein expressed only during the active phases of the cell cycle, namely in the late G\(_1\), S, G\(_2\) and M phases, but not during the resting phases (G\(_0\) and early G\(_1\)) (14). By contrast, ProExC, a specific marker of S phase-induced abnormalities, is associated with transcriptional dysregulation and abnormalities caused by the HPV E7 oncoprotein through the E2F transcription factor pathway, which serves an important role in the development and progression of cervical cancer (15,16). As ProExC is predominantly localized in the nucleus and has demonstrated high sensitivity and specificity for HSIL diagnosis (17). Furthermore, it is easier to identify compared with p16\(^{INK4a}\). It is therefore possible that p16\(^{INK4a}\), Ki-67 and ProExC can be applied as early HSIL and cervical cancer risk indicators in early cervical lesions. However, to the best of our knowledge, there have been limited studies on the predictive value of p16\(^{INK4a}\) and Ki-67 for LSIL prognosis with inconsistent results (19-21), whilst the use of ProExC staining as a biomarker for LSIL prognosis has not been previously reported.

The central aim of the present study was to investigate the expression profiles of p16\(^{INK4a}\), Ki-67, and ProExC in LSIL that progressed into HSIL and those that regressed or exhibited stable LSIL. Additionally, the prognostic value of p16\(^{INK4a}\), Ki-67 and ProExC as potential markers for LSIL progression was evaluated.

Materials and methods

Study design and patient selection. The present study followed a nested case-control design. Patients were recruited in Jixiu, Shanxi between October and December 2014 and were willing to participate in the screening program. The inclusion criteria were as follows: i) Of Han Chinese ethnicity; ii) married; iii) had resided in Shanxi for ≥1 year; iv) had current or past sexual activity; v) not pregnant; vi) no prior history of treatments associated with the cervix, 96 with LSIL, 28 with HSIL and 2 with SCC. Of the 96 women diagnosed with LSIL, 16 progressed to HSIL and 24 exhibited persistent LSIL which were classified as the case group, whilst 52 patients whose LSIL regressed spontaneously were considered the control group. A total of 4 patients were excluded due to insufficient material in the consecutive follow-up (Fig. 1).

All patients satisfying the inclusion criteria, including those diagnosed with HSIL, were followed-up every 6 months for 2 years with colposcopy and histopathological examinations. Any patients diagnosed with HSIL were treated by professional clinicians using LEEP or cervical conization, where endocervical curettage was performed simultaneously, and their follow-up was completed. All subjects provided written informed consent; the present study was approved by the Ethical Committee of Shanxi Medical University (Shanxi, China) and performed in accordance with the Declaration of Helsinki.

Liquid-based cytology and HR-HPV testing. All subjects were requested to provide two cervical tissue specimens, obtained by exfoliation using a brush during gynecological examination. One sample was automatically prepared for TCT using the Cytac Thinprep® 2000 (Cytac Corporation). Cytological classifications of disease grade were made by 2 cytopathology physicians under double-blinded conditions using parameters defined by the current 2001 Bethesda System (22). The other sample was processed for HPV genotyping by Hybri-Max™ using an HPV GenoArray Diagnostic kit (Guangdong Hybribio Biotechnology Co., Ltd.). A total of 21 types of HPV, including 15 HR-HPV serotypes and 6 low-risk serotypes can be identified by flow-through hybridization using a SLAN™-96S Real-Time PCR System (cat. no. SN 161403401; Shanghai Hongshi Medical Technology Co., Ltd.) and HHM-2 fast nucleic acid molecule hybridization instrument (cat. no. 20152400604; Guangdong Hybribio Biotechnology Co., Ltd.) (23).

Colposcopy and histopathological examination. Colposcopy was performed by gynecological specialists at the Second Hospital of Shanxi Medical University (Shanxi, China) using the Preventive Oncology International micro-biopsy protocol of directed and random biopsies (24), which results in ≥4 cervical biopsies received from patients with or without endocervical curettage (2). The histology slides were interpreted and the diagnosis was agreed upon by the two pathologists.

Immunohistochemical (IHC) detection of p16\(^{INK4a}\), Ki-67 and ProExC. All specimens were fixed in 10% formalin for 24 h at room temperature, embedded in paraffin, cut into continuous 4-μm sections and subsequently dewaxed. Following alcohol dehydration, the sections were incubated in 3% hydrogen peroxide for 20 min at room temperature to block endogenous peroxidase activity. Antigen retrieval was then performed in 10 mM citrate buffer (Dako; Agilent Technologies, Inc.) for 3 min at 100°C and PBS washing, with this step was repeated for 3 times. The sections were blocked with 10% normal goat serum (ZSGB-BIO; OriGene Technologies, Inc.) for 10 min at room temperature followed

---

2458  DING et al.: PREDICTIVE VALUE OF p16\(^{INK4a}\), Ki-67 AND ProExC IMMUNO-QUALITATIVE FEATURES
by incubation overnight at 4˚C with the following primary antibodies: Monoclonal mouse anti-p16\textsuperscript{INK4a} (1:100; cat. no. TA500036; OriGene Technologies, Inc.), monoclonal mouse anti-Ki-67 (1:100; cat. no. RMA-0542; Fuzhou Maixin Biotech Co., Ltd.) and ProExC, formed by mixing mouse monoclonal anti-MCM2 at (1:100; cat. no. sc-373702) with anti-TOP2A antibody (1:50; cat. no. sc-365916; both Santa Cruz Biotechnology, Inc.). The following day, the sections were treated in accordance with manufacturer's protocol of Histostain-SP kit (cat. no. SP-9002; ZSGB-BIO; OriGene Technologies, Inc.). Briefly, the sections were incubated with biotinylated goat anti-mouse immunoglobulin G secondary antibodies for 15 min at room temperature and horseradish peroxidase-conjugated streptavidin for 15 min at room temperature. The slides were then incubated with 3,3-diaminobenzidine for 1-2 min, washed three times using PBS, and stained with hematoxylin-eosin for 1 min. Following dehydration, the sections became transparent and were covered with neutral balsam (cat. no. G8590; Beijing Solarbio Science & Technology Co., Ltd.). Human prostate carcinoma tissues provided by the Pathology Department of the Second Hospital of Shanxi Medical University (Shanxi, China) were applied as positive controls and PBS solution without primary antibodies was used as negative control (Fig. 2).

**Light microscopic evaluation of p16\textsuperscript{INK4a}, Ki-67 and ProExC staining.** Nuclear or nuclear plus cytoplasmic staining was considered to be positive for p16\textsuperscript{INK4a} expression, whilst cytoplasmic staining alone was recorded as negative. Staining for Ki-67 and ProExC was exclusively nuclear. For p16\textsuperscript{INK4a}, a lack of staining, staining of isolated cells or small cell clusters, and a focal staining pattern were considered negative; whereas continuous, diffuse cellular staining in the basal and parabasal cell layers was considered positive (Fig. 3) (25). For Ki-67, <50% staining or staining only in the lower half of the epithelium was interpreted as negative; >50% staining or staining in more than half of the epithelium was considered positive (Fig. 4) (26). For ProExC, minor adjustments were made to the protocols previously reported by Shi et al (27) and
Pinto et al (28), where staining was assessed in accordance with the distribution of positive cells in the vertical plane of the squamous epithelium. No positive cells or positive cells occupying <33% of the squamous epithelium was interpreted as negative, whilst positive cells occupying >33% of the squamous epithelium was interpreted as positive (Fig. 5). One tissue section was analyzed per patient. Blinded analysis of all sections was conducted by two pathologists using light microscopy (BX46; Olympus Corporation) according to the protocol described previously (29).

Statistical analysis. All statistical analyses were performed using the SPSS software package (version 22.0; IBM Corp.). The data are expressed as the mean ± standard deviation or percentages. One-way ANOVA and Pearson's Chi-squared test were applied to compare continuous and categorical factors, respectively. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR), negative likelihood ratio (NLR) and Youden's index (YI) were calculated based on p16INK4a, Ki-67, and ProExC staining using the formulae of Galen and Gambino (30): Sensitivity = true positive/(true positive + false negative); specificity = true negative/(false positive + true negative); PPV = true positive/(true positive + false positive); NPV = true negative/(false negative + true negative); PLR = sensitivity/(1-specificity); NLR = (1-sensitivity)-specificity; and YI = sensitivity + specificity-1. Multinomial logistic regression analysis was used to analyze the association between the potential predictor variables and LSIL prognosis. Data from the LSIL regression group served as the reference category. The odds ratios (OR) with 95% confidence intervals (CI) were calculated based on Wald Chi-squared statistics. All statistical tests were two-tailed and P<0.05 was considered to indicate a statistically significant difference.

Results

Patient characteristics. A total of 92 cases of LSIL were found; of which 16 patients progressed to HSIL, 24 patients were diagnosed with persistent LSIL and 52 patients exhibited LSIL that regressed spontaneously. Table I displays the characteristics of the subjects in the progression, persistence and regression groups. The median ages in the progression, persistence, and regression groups were 42.8 (29-55 years), 45.9 (26-60 years) and 44.9 years (24-60 years), respectively. No significant differences were observed in age, age at menarche, age at marriage, age at first intercourse, age at first pregnancy, age at delivery, TCT, HR-HPV infection, spouse smoking history, gravidity, parity, menstrual regularity, condom use, intrauterine device use, vaginitis history, pelvic inflammation disease history, chronic disease history, or gynecological operation history among the regression, persistence and regression groups. However, there were significant differences in menopause status, where significantly fewer post-menopausal subjects were found in the progression group compared with those in the persistence and regression groups.
**p16\(^{INK4a}\), Ki-67 and ProExC staining and analysis of association with HR-HPV infection.** According to IHC, positive p16\(^{INK4a}\) was defined as observation of nuclear or nuclear plus cytoplasmic staining, whereas positive Ki-67 and ProExC expression were defined as exclusively nuclear staining. The p16\(^{INK4a}\) expression rates in the progression, persistence, and regression groups were found to be 75.0, 41.7 and 28.8%, respectively. The Ki-67 expression rates in the progression, persistence, and regression groups were 37.5, 12.5 and 7.7%, respectively. The rates of positive ProExC staining in the progression, persistence, and regression groups were 37.5, 12.5 and 7.7%, respectively. The rates of positive ProExC staining in the progression, persistence, and regression groups were 37.5, 12.5 and 7.7%, respectively (Table II). The differences in p16\(^{INK4a}\), Ki-67 and ProExC staining between the 3 groups were statistically significant (\(\chi^2=10.87, 9.03, 8.98, P<0.05\)). Specifically, the rates of p16\(^{INK4a}\), Ki-67, and ProExC staining were higher in the progression group compared with those in the persistence and regression groups (P<0.05), but the differences between the persistence and regression groups were not statistically significant (P>0.05; Table II).

To analyze the association between HR-HPV infection and p16\(^{INK4a}\), Ki-67 and ProExC staining, the 92 subjects were divided into 2 groups in accordance with their HR-HPV status. The rate of positive p16\(^{INK4a}\) expression in the HR-HPV-positive group was significantly higher compared with that in the HR-HPV-negative group. Specifically, p16\(^{INK4a}\) expression was found to significantly positively associated with HR-HPV infection (P=0.001; Table III). However, no significant associations were found between Ki-67 or ProExC expression status and HR-HPV infection (P>0.05; Table III). Of the four LSIL progression cases with negative ProExC immunostaining, three (3-4, 75%) were tested negative for HR-HPV. By contrast, the majority of (10-12, 83%) the LSIL progression cases demonstrating positive ProExC immunostaining were also tested HR-HPV positive (data not shown).

**Statistical analysis of the utility of IHC for p16\(^{INK4a}\), Ki-67, and ProExC for the prediction of HSIL progression.** Patients with progression into HSIL were classified into the progression group, whereas those with LSIL regression or persistence were assigned into the non-progression group. The rates of positive p16\(^{INK4a}\), Ki-67, and ProExC expression in the progression groups were found to be 75.0, 37.5 and 75.0%, respectively. The rates of positive expression of p16\(^{INK4a}\), Ki-67, and ProExC in the non-progression groups (persistence and regression groups) were 75.0, 37.5 and 75.0%, respectively. The rates of positive expression of p16\(^{INK4a}\), Ki-67, and ProExC in the non-progression groups (persistence and regression groups) were found to be 32.9 (25-76), 9.2 (7-76) and 35.5% (27-76), respectively (Table II).

Table IV shows the sensitivity, specificity, PPV, NPV, PLR, NLR, and YI for p16\(^{INK4a}\), Ki-67, and ProExC staining for the prediction of progression to HSIL. The sensitivity and NPV were calculated to be the highest for p16\(^{INK4a}\) (75.0 and 92.7%, respectively), whereas the specificity, PPV, PLR and NLR were the highest for Ki-67 (90.8%, 46.2%, 4.08 and 0.69, respectively). YI, which is considered a more comprehensive measure of sensitivity and specificity (31), was found to be the highest for p16\(^{INK4a}\) (42.1%), followed by ProExC (39.5%) and Ki-67 (28.3%).

**Risk factors affecting LSIL progression.** HR-HPV infection, and staining for p16\(^{INK4a}\), Ki-67 and ProExC were examined...
Table II. Comparison of p16\(^{INK4a}\), Ki67, ProExC expression in the progression, persistence and regression groups.

### A. p16\(^{INK4a}\)

| Expression status | Progression (n=16) | Persistence (n=24) | Regression (n=52) | $\chi^2$ | P-value |
|-------------------|-------------------|-------------------|------------------|------|--------|
| Negative          | 4 (25.0%)         | 14 (58.3%)        | 37 (71.2%)       |      | 0.004  |
| Positive          | 12 (75.0%)        | 10 (41.7%)        | 15 (28.8%)       | 10.87|        |

### B. Ki-67

| Expression status | Progression (n=16) | Persistence (n=24) | Regression (n=52) | $\chi^2$ | P-value |
|-------------------|-------------------|-------------------|------------------|------|--------|
| Negative          | 10 (62.5%)        | 21 (87.5%)        | 48 (92.3%)       | 9.03 | 0.011  |
| Positive          | 6 (37.5%)         | 3 (12.5%)         | 4 (7.7%)         |      |        |

### C. ProExC

| Expression status | Progression (n=16) | Persistence (n=24) | Regression (n=52) | $\chi^2$ | P-value |
|-------------------|-------------------|-------------------|------------------|------|--------|
| Negative          | 4 (25.0%)         | 14 (58.3%)        | 35 (67.3%)       | 8.98 | 0.011  |
| Positive          | 12 (75.0%)        | 10 (41.7%)        | 17 (32.7%)       |      |        |

p16\(^{INK4a}\), cyclin-dependent kinase inhibitor 2A; Ki-67, marker of proliferation Ki-67; ProExC, DNA topoisomerase II\(\alpha\) and minichromosome maintenance complex component 2 antibody cocktail.

Table III. Association analysis between p16\(^{INK4a}\), Ki67 and ProExC expression with HR-HPV infection.

### A. p16\(^{INK4a}\)

| HR-HPV infection | Negative (%) | Positive (%) | $\chi^2$ | P-value |
|------------------|-------------|-------------|--------|--------|
| Negative         | 31 (79.5)   | 24 (45.3)   | 10.933 | 0.001  |
| Positive         | 8 (20.5)    | 29 (54.7)   |        |        |

### B. Ki-67

| HR-HPV infection | Negative (%) | Positive (%) | $\chi^2$ | P-value |
|------------------|-------------|-------------|--------|--------|
| Negative         | 34 (87.2)   | 45 (84.9)   | 0.096  | 0.757  |
| Positive         | 5 (12.8)    | 8 (15.1)    |        |        |

### C. ProExC

| HR-HPV infection | Negative (%) | Positive (%) | $\chi^2$ | P-value |
|------------------|-------------|-------------|--------|--------|
| Negative         | 23 (59.0)   | 30 (56.6)   | 0.052  | 0.82   |
| Positive         | 16 (41.0)   | 23 (43.4)   |        |        |

HR-HPV, high-risk human papilloma virus; p16\(^{INK4a}\), cyclin-dependent kinase inhibitor 2A; Ki-67, marker of proliferation Ki-67; ProExC, DNA topoisomerase II\(\alpha\) and minichromosome maintenance complex component 2 antibody cocktail.
by multivariate logistic regression analysis (significance level, α=0.05; permitted error =0.10) to obtain a statistically significant equation. Menopausal status, which was found to be a significant variable in the present study (Table I), was also included as one of the items in this analysis. The logistic regression models revealed ProExC expression to be an independent risk factor for LSIL progression after 2 years. The risk of progression for LSIL patients with positive ProExC staining was found to be 6.11-fold higher compared with that of patients negative for ProExC staining (95% CI, 1.438-25.997; Table V).

**Discussion**

In the present study, IHC was performed to detect and measure the expression of \( \text{p}16^{\text{INK4a}} \), Ki-67, and ProExC in cervical specimens. IHC is a conventional method in clinical diagnosis where there is no strict requirement for the size of tissues.

The present nested case-control study demonstrated that although IHC staining for \( \text{p}16^{\text{INK4a}} \), Ki-67 and ProExC can be applied to predict HSIL progression, only ProExC staining was an independent risk factor for LSIL progression after 2 years. To the best of our knowledge, the present study was the first to analyze the predictive value of ProExC staining compared with \( \text{p}16^{\text{INK4a}} \) and Ki-67 for the progression of LSIL among Han Chinese women.

The \( \text{p}16^{\text{INK4a}} \) tumor suppressor protein inhibits the cyclin-dependent kinases that regulate progression through the cell cycle by phosphorylating the retinoblastoma protein. In most cervical malignancies, the functional inactivation of pRb by HPV E7 results in the overexpression of \( \text{p}16^{\text{INK4a}} \) (32). Previous studies have demonstrated that \( \text{p}16^{\text{INK4a}} \) can be used as a prognostic marker for disease progression and infection by HR-HPV (33,34). Consistent with this notion, it was found in the present study that \( \text{p}16^{\text{INK4a}} \) expression was associated with HR-HPV infection. The value of \( \text{p}16^{\text{INK4a}} \) in CIN grading has been previously reported. In 2012, the American Society for Colposcopy and Cervical Pathology and the Lower Anogenital Squamous Terminology project recognized the value of \( \text{p}16^{\text{INK4a}} \) by proposing a new 2-stage classification system; specifically for LSIL to include CIN1 and \( \text{p}16^{\text{INK4a}} \)-negative CIN2, and for HSIL to include \( \text{p}16^{\text{INK4a}} \)-positive CIN2 and CIN3 (35). However, studies on the value of \( \text{p}16^{\text{INK4a}} \) in LSIL progression are limited, with inconsistent findings. In the past decade, the majority of studies suggested that patients with \( \text{p}16^{\text{INK4a}} \)-positive LSIL were at higher risks of developing HSIL (36-38). Liao et al (19) conducted a prospective population-based study to evaluate if the overexpression of \( \text{p}16^{\text{INK4a}} \) in LSIL biopsies can accurately predict HSIL progression and found that \( \text{p}16^{\text{INK4a}} \) expression in LSIL on initial diagnosis was associated with an increased risk of HSIL in 2 years (OR=1.43; 95% CI, 0.52-3.91). However, Sagasta et al (20) showed that HSIL/CIN2-3 exhibited higher positive rates for \( \text{p}16^{\text{INK4a}} \) staining compared with persistent or regressing LSIL/CIN1 lesions (71 vs. 44%), but found that \( \text{p}16^{\text{INK4a}} \) immunostaining was not associated with risk of HSIL [hazard ratio 1.6 (95% CI, 0.9-2.6); P=0.095]. Sagasta et al (20) subsequently concluded that \( \text{p}16^{\text{INK4a}} \) overexpression in biopsies from women with LSIL was a poor predictor in LSIL progression, with little or no value as a marker in clinical practice. Results from the present study were consistent with the latter study. The \( \text{p}16^{\text{INK4a}} \) expression rate in the progression group was higher compared with the persistence and regression groups, and the YI for \( \text{p}16^{\text{INK4a}} \) was the highest of the markers tested, suggesting that \( \text{p}16^{\text{INK4a}} \) was the most accurate marker for predicting HSIL progression. However, \( \text{p}16^{\text{INK4a}} \) expression was not an independent risk factor for LSIL progression after 2 years, suggesting that \( \text{p}16^{\text{INK4a}} \) can be used to increase the accuracy of the HSIL diagnosis but not in predicting LSIL progression.

Ki-67 is a DNA-binding enzyme which is utilized widely to measure tumor cell proliferation and evaluate the degree of tumor malignancy and prognosis. A number of studies have previously reported that Ki-67 expression is positively associated with the grade of cervical lesions (39-41). In 2015, the Bethesda guidelines recommended \( \text{p}16^{\text{INK4a}} \)/Ki-67 double staining as part of the cytological diagnostic procedure (42). A dual \( \text{p}16 \)/Ki-67 immunocytochemistry assay is now available for use as an adjunct test for cervical cancer screening (43). In a previous study, the \( \text{p}16^{\text{INK4a}} \)/Ki-67 dual staining strategy was tested in a large, prospective clinical trial involving 27,456 women; where \( \text{p}16^{\text{INK4a}} \)/Ki-67 dual staining cytology testing was found to increase the sensitivity of HSIL diagnosis whilst maintaining high specificity (44). In another study, Kanthiya et al (45) found that Ki-67 expression was demonstrated in 75.4% of CIN2-3, 22.6% of CIN1 and 11.3% clinical specimens with non-dysplasia. These results suggest that Ki-67 overexpression can also be used as a marker for the tendency for progression in early cervical lesions. However, only one study, which was conducted by Kruse et al (46), included samples from patients with CIN1 (n=25) and CIN2 (n=65) and investigated Ki-67 IHC in CIN progression. They found that the prognostic value of the Ki-67 progression-risk model exceeded the value of the histopathological CIN grade for the prediction of progression to a higher CIN grade. Although it was found that the Ki-67 expression rate was higher in the

| Variable          | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | PLR    | NLR    | YI (%) |
|------------------|----------------|----------------|---------|---------|--------|--------|--------|
| p16^{INK4a} positivity | 75.00          | 67.10          | 32.40   | 92.70   | 2.28   | 0.38   | 42.10  |
| Ki-67 positivity  | 37.50          | 90.80          | 46.20   | 87.30   | 4.08   | 0.69   | 28.30  |
| ProExC positivity | 75.00          | 64.50          | 30.80   | 92.40   | 2.11   | 0.39   | 39.50  |

PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; YI, Youden's index.
Table V. Multivariate analysis of potential risk factors for LSIL progression or persistence in patients with different cervical intraepithelial neoplasia prognosis.

A. LSIL persistence

| Variable                  | \( \beta \) | SE  | Wald | P-value | OR     | Lower  | Upper  |
|---------------------------|-------------|-----|------|---------|--------|--------|--------|
| HR-HPV infection          | 0.607       | 0.549 | 1.223| 0.269   | 1.834  | 0.626  | 5.376  |
| Menopause status          | 0.7         | 0.569 | 1.517| 0.218   | 2.015  | 0.661  | 6.141  |
| p16\(^{INK4a}\) staining | 0.407       | 0.584 | 0.485| 0.486   | 1.502  | 0.478  | 4.717  |
| Ki67 staining             | 0.57        | 0.867 | 0.432| 0.511   | 1.767  | 0.323  | 9.664  |
| ProExC staining           | 0.579       | 0.547 | 1.211| 0.29    | 1.785  | 0.611  | 5.217  |

B. LSIL progression

| Variable                  | \( \beta \) | SE  | Wald | P-value | OR     | Lower  | Upper  |
|---------------------------|-------------|-----|------|---------|--------|--------|--------|
| HR-HPV infection          | 1.502       | 0.844 | 3.167| 0.075   | 4.489  | 0.859  | 23.465 |
| Menopause status          | -0.835      | 1.159 | 0.519| 0.471   | 0.434  | 0.045  | 4.208  |
| p16\(^{INK4a}\) staining | 1.038       | 0.771 | 1.812| 0.178   | 2.823  | 0.623  | 12.791 |
| Ki67 staining             | 1.526       | 0.91  | 2.808| 0.094   | 4.598  | 0.772  | 27.386 |
| ProExC staining           | 1.811       | 0.738 | 6.011| 0.014   | 6.114  | 1.438  | 25.997 |

LSIL regression was used as the reference group. OR, odds ratio; CI, confidence interval; Wald, Wald Chi-squared statistic. LSIL, low-grade squamous intraepithelial lesions; p16\(^{INK4a}\), cyclin-dependent kinase inhibitor 2A; Ki-67, marker of proliferation Ki-67; ProExC, DNA topoisomerase II\(\alpha\) and minichromosome maintenance complex component 2 antibody cocktail; HR-HPV, high-risk human papillomavirus; SE, standard error.

The overexpression of MCM2 provides the link between oncogenic HPV infection and the molecular event of cervical dysplasia (49), which is consistent with data from the present study. Of the four LSIL progression cases with negative ProExC immunostaining, three (3-4, 75%) were negative for HR-HPV. By contrast, the majority of (10-12, 83%) the LSIL progression cases demonstrating positive ProExC immunostaining were also tested HR-HPV positive. Additionally, only positive ProExC staining was found to be an independent risk factor for LSIL progression in 2 years, suggesting that ProExC-positive LSIL pose a higher risk of developing into HSIL.

To conclude, to the best of our knowledge, this is the first study to report that compared with p16\(^{INK4a}\) and Ki-67, only ProExC staining was an independent risk factor for LSIL progression over 2 years. This study provides a new insight into identifying LSIL patients at a higher risk of malignant progression, potentially facilitating more cost-effective and efficient interventions.

Acknowledgements

We wish to thank Dr Ying Wang and Dr Xiaoqin Zhang of The Department of Pathology of the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China for the pathological analysis of tissue sections.
Funding
This research was supported by the National Natural Science Foundation of China (grant nos. 81703313, 81702583 and 81473060) and the Special Public Welfare Industry Research of National Health and Family Planning Commission (grant no. 201402010).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions
LD, LS, WZ and JW conceived and designed the present study. XL, WG and ZQ collected the data and performed the experiments. LD and WZ performed the data analysis and interpretation. LD and LS wrote the manuscript. All the authors have read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Shanxi Medical University Science Research Ethics Committee (Shanxi, China), and written informed consent was obtained from all patients prior to publication.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin 66: 115-132, 2016.
2. Wang Z, Wang J, Fan J, Zhao W, Yang X, Wu L, Li D, Ding L, Wang W, Xu J, et al: Risk factors for cervical intraepithelial neoplasia and cervical cancer in Chinese women: Large study in Jiexiu, Shanxi Province, China. J Cancer 8: 924-932, 2017.
3. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X and He J: Annual report on status of cancer in China, 2010. Chin J Cancer 8: 924‑932, 2017.
4. Schlecht NF, Plat R, Duarte-Franco E, Costa MC, Sobrinho JP, Prado JC, Ferencyz A, Rohan TE, Villa LL and Franco EL: Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst 95: 1336-1343, 2003.
5. Pretet JL, Jacquard AC, Saumier M, Clavel C, Dacher R, Gondry J, Pradat P, Soubeyrand B, Leocmach Y, Mougin C, et al: Human papillomavirus genotype distribution in low-grade squamous intraepithelial lesions in France and comparison with CIN2-3 and invasive cervical cancer: The EDiTH III study. Gynecol Oncol 110: 179-184, 2008.
6. Koeneman MM, Kruitwagen RF, Nijman HW, Slange BF, Van Gorp T and Kruse AJ: Natural history of high-grade cervical intraepithelial neoplasia: A review of prognostic biomarkers. Expert Rev Mol Diagn 15: 527-546, 2015.
7. Zhao WH, Hao M, Cheng XT, Yang X, Wang ZL, Cheng KY, Liu FL and Bai YX: c-myc gene copy number variation in cervical exfoliated cells detected on fluorescence in situ hybridization for cervical cancer screening. Gynecol Obstet Invest 81: 416-423, 2016.
8. Choi YJ and Park JS: Clinical significance of human papillomavirus genotyping. J Gynecol Oncol 27: e21, 2016.
9. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Pin squin A, Castle PE, Solomon D and Burik R: Proyecto Epidemiologico Guanacaste G: Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100: 513-517, 2008.
10. Egawa N, Egawa K, Griffin H and Doorbar J: Human papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses 4: 3863-3890, 2012.
11. Zhao W, Hao M, Wang Y, Feng N, Wang Z, Wang W and Ding L: Association between folate status and cervical intraepithelial neoplasia. Eur J Clin Nutr 70: 837-842, 2016.
12. Walls AE and Bose S: p16, Ki-67, and BD ProExC immunohistochemical staining of cervical intraepithelial neoplasia. Hum Pathol 40: 957-964, 2009.
13. Ortega S, Malumbres M and Barbacid M: Cyclin D-dependent kinases INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87, 2002.
14. Takagi M, Sueishi M, Saiwaki T, Kametaka T and Yoneda Y: A novel nuclear protein, NIEF, interacts with the forkhead-associated domain of Ki-67 antigen in mitosis. J Biol Chem 276: 25386-25391, 2001.
15. Leone G, DeGregori J, Yan Z, Jakoi L, Ishida S, Williams R and Nevin JR: E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 12: 2120-2130, 1998.
16. Goodwin EC and DiMaio D: Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. Proc Natl Acad Sci USA 97: 12513-125138, 2000.
17. Hallouss RH, Akropolat I, Jin Zhai Q, Schwartz MR and Mody DR: Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: A pilot study. Cancer 114: 474-480, 2008.
18. Badr RE, Walts AE, Chung F and Bose S: BD ProEx C: A sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol 32: 899-906, 2008.
19. Liao GD, Sellors JW, Sun HK, Zhang X, Bao YP, Jeronimo J, Chen W, Zhao FH, Song Y, Cao Z, et al: p16 INK4A Immunohistochemical staining and predictive value for progression of cervical intraepithelial neoplasia grade 1: A prospective study in China. Int J Cancer 134: 1715-1724, 2014.
20. Sagasta A, Castillo P, Saco A, Torné A, Esteve R, Marimon L, Ordi J and Del PM: p16 staining has limited value in predicting the outcome of histological low-grade squamous intraepithelial lesions of the cervix. Med Pathol 29: 51-59, 2016.
21. Silva DC, Goncalves AK, Cobucci RN, Mendonca RC, Lima PH and Júnior GC: Immunohistochemical expression of P16, Ki67 and P53 in cervical lesions: A systematic review. Pathol Res Pract 213: 723-729, 2017.
22. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, et al: The 2001 Bethesda system: Terminology for reporting results of cervical cytology. JAMA 287: 2114‑2119, 2002.
23. Tao P, Zheng W, Wang Y and Bian ML: Sensitive HPV genotyping based on the flow-through hybridization and gene chip. J Biomed Biotechnol 2012: 938780, 2012.
24. Bornstein J, Bentley J, Böszé P, Girardi F, Haeffner H, Menton P, Perrotta M, Previdelle W, Russell P, Sideri M, et al: 2011 colposcopic terminology of the international federation for cervical pathology and colposcopy, Obstet Gynecol 120: 166-172, 2012.
25. Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luft RD, McCalmon T, Nayar R, Palefsky JM, Stoler MH, et al: The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: Background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 32: 76-115, 2013.
26. Chinman MS, Wu TT, Chandan VS, Lohse CM and Zhang L: Ki-67 and ProExC are useful immunochemical markers in esophageal squamous intraepithelial neoplasia. Hum Pathol 42: 1430-1437, 2011.
27. Shi J, Liu H, Willkerson M, Huang Y, Meschter S, Dupree W, Schuerm M and Lin F: Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase II alpha, ProEx C, and p16INK4a-ProEx C in cervical squamous intraepithelial lesions. Hum Pathol 38: 1335-1344, 2007.
28. del Pino M, Garcia S, Fuste V, Alonso I, Fuste P, Torne A and Cortecchia S, Galanti G, Sgadari C, Costa S, De Lillo M, Branca M, Ciotti M, Santini D, Di Bonito L, Giorgi C, Liu HQ, Wang YH, Wang LL and Hao M: INK4A and 16p.

29. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Youden WJ: Index for rating diagnostic tests. Cancer 3: 32-35, 2003.

30. Galen RS and Gambino SR: Beyond Normality: The Predictive Value for Rating Diagnostic Tests. John Wiley, Sons, New York, NY, p1-273, 1975.

31. Youden WJ: Index for rating diagnostic tests. Cancer 3: 32-35, 1950.

32. Khleif SN, DeGregori J, Yee CL, Otterson GA, Kaye FJ, Nevins JR and Howley PM: Inhibition of cyclin D-CDK4-CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci USA 93: 4350-4354, 1994.

33. Liu HQ, Wang YH, Wang LL and Hao M: P16INK4A and survivin: Diagnostic and prognostic markers in cervical intraepithelial neoplasia and cervical squamous cell carcinoma. Exp Mol Pathol 99: 44-49, 2015.

34. Branca M, Ciofetti M, Santini D, Di Bonito L, Giorgi C, Benedetto A, Paba P, Favalì C, Costa S, Agarossi A, et al: P16INK4A Expression is related to grade of cin and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome. Int J Gynecol Pathol 23: 354-365, 2004.

35. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, McCalet A, Nayar R, Palefsky JM, Stoler MH, et al: The lower anogenital squamous terminology standardization project for HPV associated lesions: Background and consensus recommendations from the College of American Pathologists and the American society for colposcopy and cervical pathology. J Low Genit Tract Dis 16: 205-242, 2012.

36. Corteccia S, Galanti G, Sgadari C, Costa S, De Lillo M, Caprara L, Barillari G, Monini P, Nannini R, Ensoli B and Bucchi L: Follow-up study of patients with cervical intraepithelial neoplasia grade 1 overexpressing p16Ink4a. Int J Gynecol Cancer 23: 1663-1669, 2013.

37. del Pino M, Garcia S, Fuste V, Alonso I, Fuste P, Torne A and Ordi J: Value of p16(INK4a) as a marker of progression-regression in cervical intraepithelial neoplasia grade 1. Am J Obstet Gynecol 201: 488.e1-7, 2009.

38. Harriri J and Öster A: The negative predictive value of p16INK4a to assess the outcome of cervical intraepithelial neoplasia 1 in the uterine cervix. Int J Gynecol Pathol 26: 223-228, 2007.

39. Ozaki S, Zen Y and Inoue M: Biomarker expression in cervical intraepithelial neoplasia: Potential progression predictive factors for low-grade lesions. Hum Pathol 42: 1007-1012, 2011.

40. Hanprasertpong J, Tungsinmun Kong K, Chichareon S, Wootipoom V, Geater A, Buhachat R and Boonyapipat S: Correlation of p53 and Ki-67 (MIB-1) expressions with clinicopathological features and prognosis of early stage cervical squamous cell carcinomas. J Obstet Gynecol Res 36: 572-580, 2010.

41. Mitildaunz A, Arechivo A, Rezeberga D and Isajevs S: Expression of p53, p53 and Ki-67 in patients with cervical intraepithelial neoplasia. Turk Patoloji Derg 33: 9-16, 2017.

42. Nayar R and Willbur DC: The Bethesda System for Reporting Cervical Cytology Definitions, Criteria, and Explanatory Note, 3rd ed (ed). Switzerland: Springer International Publishing, 103-134, 2015.

43. Sekoranta D and Repele Pokter A: Traging atypical squamous cells-cannot exclude high-grade squamous intraepithelial lesion With p16-Ki67 dual stain. J Low Genit Tract Dis 21: 108-111, 2017.

44. Torresello ML, Buonaguro L, Giorgi-Rossi P and Buonaguro FM: Viral and cellular biomarkers in the diagnosis of cervical intraepithelial neoplasia and cancer. Biomed Res Int 2013: 519-619, 2013.

45. Kanthiya K, Khunnarong J, Tantjiitgamol S, Puripat N and Tanvanich S: Expression of the p53 and Ki67 in cervical squamous intraepithelial lesions and cancer. Asian Pac J Cancer Prev 17: 3201-3202, 2016.

46. Kruse AJ, Baak JP, Janssen EA, Kjelelevd KH, Fiane B, Lowslet K, Bergh J and Robjoy S: Ki67 predicts progression in early CIN: Validation of a multivariate progression-risk model. Cell Oncol 26: 13-20, 2004.

47. Osaki M, Osaki M, Yamashita H, Shomori K, Yoshida H and Ito H: Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: Correlations with Ki-67 and P53 expression, and apoptosis. Int J Mol Med 10: 161-168, 2002.

48. Gibbons D, Fogt F, Kasznica J, Holden J and Nikulasson S: Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions. Mod Pathol 10: 409-413, 1997.

49. Ishimi Y, Okayasu I, Kato C, Kwon JW, Kimura H, Yamada K and Song SY: Enhanced expression of Mcm proteins in cancer cells derived from uterine cervix. Eur J Biochem 270: 1089-1101, 2003.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.